Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤¾ÏÀÇ Áø´Ü ¹× ÃßÀû °Ë»ç¿¡¼­ Bladder Tumor Antigen(BTA) Stat °Ë»ç¿Í ¿ä¼¼Æ÷°Ë»çÀÇ ºñ±³ Comparison of the Bard BTA Stat Test and Cytology in the Diagnosis and Follow-up of Bladder Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 7È£ p.891 ~ 895
Á¤¿µ¹ü, Á¤¿µ¹ü, ±èÇüÁø, ±èÇüÁø,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤¿µ¹ü (  ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇ°úÇבּ¸¼Ò

Á¤¿µ¹ü (  ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±èÇüÁø (  ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±èÇüÁø (  ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇ°úÇבּ¸¼Ò

Abstract

¼­·Ð
¹æ±¤¾ÏÀº ±¹³»¿¡¼­ ºñ´¢±â°è¾Ï Áß °¡Àå ¹ß»ý ºóµµ°¡ ³ôÀº Á¾¾çÀ¸·Î ¹æ±¤°æ °Ë»çÀÇ À°¾ÈÀû
¼Ò°ßÀ̳ª Á¶Á÷°Ë»ç, ¿ä¼¼Æ÷°Ë»ç·Î Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ´Ù. ¹æ±¤°æÇÏ¿¡¼­ Á¶Á÷°Ë»ç¸¦ ½ÃÇà
ÇÏ¿© È®ÁøÇÒ ¼ö ÀÖÁö¸¸ ¹æ±¤°æ °Ë»ç´Â ħ½ÀÀûÀ̾ ȯÀÚ¿¡°Ô ºÒÆíÇÔÀ» ÁÖ°í °£È¤ ½Ã¾ß¿¡¼­
º¼ ¼ö ¾ø´Ù´Â ´ÜÁ¡ÀÌ ÀÖÀ¸¸ç, ¿ä¼¼Æ÷°Ë»ç´Â ºñ±³Àû ƯÀ̵µ°¡ ³ôÁö¸¸ Àúº´±â, ÀúºÐÈ­µµÀÇ ¹æ
±¤¾Ï¿¡¼­´Â ¹Î°¨µµ°¡ ³·°í Æǵ¶ÀÚÀÇ ÁÖ°ü¿¡ Á¿ìµÇ´Â Àü¹®¼ºÀÌ ¿ä±¸µÇ¸ç ½Ã°£ÀÌ ¿À·¡ °É¸°
´Ù´Â ´ÜÁ¡ÀÌ ÀÖ´Ù.
ÃÖ±Ù¿¡ ¹æ±¤¾Ï Áø´ÜÀ» À§ÇÑ BTA(bladder tumor an tigen)°Ë»ç, BTA stat °Ë»ç, BTA
TRAK °Ë»ç, NMP(no-clear matrix protein)-22 °Ë»ç, ¿äÁß telomeraseÃøÁ¤, FDP
(fibrinogen degradation products)ÃøÁ¤, hyaluronic acid-hyaluronidase °Ë»ç, Lewis X ¸é¿ª
¼¼Æ÷ °Ë»ç µî°ú °°Àº ºñħ½ÀÀûÀÌ°í ½ÃÇàÀÌ Æí¸®ÇÑ ¿©·¯ °¡Áö ¹æ¹ýÀÌ ¼Ò°³µÇ°í ÀÖÀ¸¸ç, ±×Áß
BTA stat °Ë»ç´Â ´Ù¸¥ »óÇÇ ¼¼ Æ÷ÁÖ¿¡¼­´Â »ý¼ºÀÌ ¾ÈµÇ°í ÀÎü ¹æ±¤¾Ï ¼¼Æ÷ÁÖ¿¡¼­¸¸ »ý¼º
µÇ´Â human complement factor H-related protein)(hCFHrp)À» °ËÃâÇÏ´Â Á¤¼ºÀûÀÎ °Ë»ç¹ýÀ¸
·Î ȯÀÚ°¡ ¹è´¢ÇÑ ¼Ò·®ÀÇ ¼Òº¯À» äÃëÇÏ¿© ºñħ½ÀÀûÀÌ°í ªÀº ½Ã°£ ³»¿¡ °á°ú¸¦ ¾Ë ¼ö ÀÖ´Â
°£ÆíÇÑ ¹æ¹ýÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
º» ±³½Ç¿¡¼­´Â ¹æ±¤¾Ï ȯÀÚ¿¡¼­ BTA stat°Ë»çÀÇ ÀÓ»óÀû ÀÇÀǸ¦ ¾Ë¾Æº¸±â À§ÇØ ¹æ±¤¾Ï ȯ
ÀÚ¿Í °æ¿äµµ Á¾¾ç ÀýÁ¦¼ú ÈÄ ÃßÀû °üÂû ÁßÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î ¹æ±¤ ¼¼Ã´ ¿ä¼¼Æ÷°Ë»ç¿Í ºñ±³
ÇØ º¸¾Ò´Ù.

Purpose : The BTA stat test is a one-step immunochromatographic assay to detect
bladder tumor antigen in the urine. We evaluated the efficacy of the BTA stat test and
blader wash cytology(BWC) in the detection and follow-up of bladder cancer.
Materials and Methods: A voided urine sample for BTA stat test and bladder washing
urine for cytology were obtained. The BTA stat test with or without BWC was
performed in normal volunteers(n=20), patients with hematuria of unknown origin(n=29),
patients with benign genitourinary(GU) disease(n=17), patients with other GU
cancer(n=12), patients with bladder cancer(n=46) and patients with a history of bladder
cancer(n=54).
Results: The overall sensitivities of the BTA stat and BWC in bladder cancer were
69.6% and 41.3%, respectively(p<0.01). For 72 or higher stage tumors, sensitivity was
94.1% for BTA stat and 64.7% for BWC(p<0.05). Grade ¥± tumors were detected at
64.3% with BTA stat and 35.7% with BWC(p<0.05). The sensitivities of the BTA stat
and BWC in the follow-up of patients a%or transurethral resection of bladder tumor
were 45.5%(5/11) and 27.3%(3/11), respectively. The specificities of the BTA stat and
BWC in the same patients were 88.4%(38/43) and 100%(43/43), respectively(p<0.05). The
specificity in patients with hematuria but without disease was 69% for BTA stat and
100% for BWC. The specificities of the BTA stat in healthy volunteers, benign GU
disease and other GU cancer were 55%, 82.4% and 75%, respectively.
Conclusions: Our results demonstrate that BTA stat test is a simple, noninvasive test
that is superior to bladder wash cytology for detection of bladder cancer in its
sensitivity and a useful adjunct of cystoscopy in surveillance and diagnosis of bladder
cancer. However, the BTA stat test can not replace cystoscopy due to low specificity.

Å°¿öµå

Bladder neoplasms; Cytology; BTA;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS